Olema Pharmaceuticals, Inc.
Clinical trials sponsored by Olema Pharmaceuticals, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced breast cancer: OP-1250 faces off against standard care Results expected Oct 2026 (estimated)
- New cancer drug OP-3136 enters first human tests Results expected May 2027 (estimated)
-
New hope for advanced breast cancer: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial is testing a new drug called palazestrant (OP-1250) combined with ribociclib against the standard letrozole plus ribociclib for people with ER+, HER2- advanced breast cancer who haven't had prior treatment. About 1,000 participants will be randomly assigned to …
Phase 3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New cancer drug OP-3136 enters first human tests
Disease control Recruiting nowThis early-phase study tests a new drug called OP-3136 in people with advanced breast, lung, or prostate cancers that have not responded to other treatments. The drug works by blocking certain enzymes that help cancer cells grow. The study will first find a safe dose, then test i…
Phase 1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC